EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Incidence of laboratory-defined severe intravascular haemolysis across commercially available pulsed field ablation technologies for atrial fibrillation

Stavros E Mountantonakis iD, Nicholas Beccarino iD, Humail Patel iD, Andres Castillo, Taha Siddiqui, Madhav Bhatt iD, Jonas Leavitt iD, Kristie M Coleman iD

Europace · 01.09.2025 · 27 (9)

DOI: 10.1093/europace/euaf185 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Europace, online erschienen am 22.08.2025. Verfasst von Stavros E Mountantonakis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Arrhythmias, Northwell Cardiovascular Institute, 2000 Marcus Ave, Suite 300, New Hyde Park, NY 11042-1069, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Hemolysis, Catheter Ablation, Renal Insufficiency. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Renal failure due to intravascular haemolysis (IH) has been reported after pulsed field ablation (PFA) of atrial fibrillation (AF). However, IH incidence using the accepted laboratory criteria is unknown. Methods and results In this prospective observational study (Sept 2024–May 2025), consecutive patients undergoing PFA for AF with pentaspline (PS), circular array (CA), or lattice tip (LT) catheters were included. Pre- and post-procedural labs and haemolysis biomarkers were collected. Significant IH was defined as post-procedure free plasma haemoglobin > 100 mg/dL per haematology criteria. Logistic regression (pooled and stratified) was used to identify IH predictors. Among 245 patients (66.9 ± 10.6 years; 68.2% male; 48.2% persistent), PFA was performed using the LT (62), PS (108), or CA (75) catheters. There was a significant difference in the incidence of IH across technologies (37.0%, 26.1%, and 14.7% for PS, CA, and LT, P = 0.002). No demographic or clinical parameters were associated with higher IH risk, while the use of PS was the only independent predictor [odds ratio (OR) 3.42, P = 0.001] of IH. The number of PF lesions increased risk for IH only within the PS group (OR 1.03, P = 0.049). Routine post-ablation laboratories had poor sensitivity/specificity to define severe IH.

Conclusion

Although over 17% of the cohort met the haematologic definition for significant IH, the absence of clinically significant renal impairment suggests that this threshold may not accurately reflect clinically meaningful haemolysis following PFA. The absence of clinical predictors or laboratory surrogates suggests that the rare risk of renal injury must be balanced with the well-established benefits of PFA when lesions are delivered in moderation optimizing tissue contact.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHemolysisCatheter AblationRenal InsufficiencyHumansMaleFemaleAgedIncidenceProspective StudiesMiddle AgedRisk Factors

Stichwörter der Autor:innen

Atrial fibrillationClinical implementationIntravascular haemolysisPulsed field ablation

Autor:innen und Institutionen

  • Center for Arrhythmias, Northwell Cardiovascular Institute, 2000 Marcus Ave, Suite 300, New Hyde Park, NY 11042-1069, USA.
  • Department of Electrophysiology, Lenox Hill Hospital, 100 East 77th Street, New York, NY 10075, USA.

ORCID-Profile: Stavros E Mountantonakis, Nicholas Beccarino, Humail Patel, Madhav Bhatt, Jonas Leavitt, Kristie M Coleman

Zitieren

APA

Mountantonakis, S. E., Beccarino, N., Patel, H., Castillo, A., Siddiqui, T., Bhatt, M., Leavitt, J., & Coleman, K. M. (2025). Incidence of laboratory-defined severe intravascular haemolysis across commercially available pulsed field ablation technologies for atrial fibrillation. Europace, 27(9). https://doi.org/10.1093/europace/euaf185

Vancouver

Mountantonakis SE, Beccarino N, Patel H, Castillo A, Siddiqui T, Bhatt M, et al. Incidence of laboratory-defined severe intravascular haemolysis across commercially available pulsed field ablation technologies for atrial fibrillation. Europace. 2025;27(9). doi:10.1093/europace/euaf185

BibTeX
@article{Mountantonakis2025,
  author = {Mountantonakis, Stavros E and Beccarino, Nicholas and Patel, Humail and Castillo, Andres and Siddiqui, Taha and Bhatt, Madhav and Leavitt, Jonas and Coleman, Kristie M},
  title = {Incidence of laboratory-defined severe intravascular haemolysis across commercially available pulsed field ablation technologies for atrial fibrillation},
  journal = {Europace},
  year = {2025},
  volume = {27},
  number = {9},
  doi = {10.1093/europace/euaf185}
}
Kostenlos starten →